Baxter Reports $45M Boost From COVID-19 Demand In Q1
The COVID-19 pandemic has increased demand for products from all of Baxter’s businesses except its advanced surgery division. Overall, the diversified company’s global sales were up 8% in the first quarter.
You may also be interested in...
COVID-19 Continues To Drive Demand For Baxter’s Acute Therapies Portfolio
Demand for Baxter's acute therapy products helped offset declines across its advanced surgery, pharmaceuticals and medication-delivery businesses in the second quarter.
Plan To ‘Reopen’ America Gradually Allows Return Of Elective Orthopedic, Colon, Eye Surgeries
Under guidelines recently unveiled by President Trump, US health care facilities could gradually start phasing-in more elective surgeries, including commonly performed operations that were postponed due the COVID-19 outbreak – many of which involve extensive device use. Elective surgeries include orthopedic joint replacement procedures, colonoscopies and cataract-correcting procedures that could resume as early as May under Trump’s plan.
COVID-19: Dialysis Machine Makers Respond To Surge In Demand
Baxter and Fresenius are taking extraordinary steps to respond to the flood of COVID-19 patients requiring continuous renal replacement therapy.